LBRX
LB Pharmaceuticals Inc Common Stock NASDAQ Listed Sep 11, 2025$48.00
-0.37%
vs $48.18
Mkt Cap $1.4B
52w Low $13.36
96.8% of range
52w High $49.14
50d MA $33.10
200d MA $25.53
P/E (TTM)
—
EV/EBITDA
—
P/B
4.0x
Debt/Equity
0.0x
ROE
-8.4%
P/FCF
-34.4x
RSI (14)
88.90
ATR (14)
$3.04
Beta
-0.18
50d MA
$33.10
200d MA
$25.53
Avg Volume
385.8K
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
CIK (SEC)
Phone
212 605 0300
One Pennsylvania Plaza · New York, NY 10119 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | AMC | -0.75 | -0.67 | +10.7% | 31.13 | -1.1% | +3.8% | -2.8% | -5.6% | -6.5% | -1.7% | — |
| Mar 26, 2026 | AMC | -0.45 | -0.45 | +0.0% | 24.53 | +1.7% | -2.8% | -2.5% | +6.1% | +0.6% | +3.5% | — |
| Nov 6, 2025 | AMC | -0.57 | -0.61 | -7.0% | 15.51 | +0.3% | -1.0% | -4.8% | +9.4% | -5.6% | -1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 21 | BMO Capital Markets | Initiates | Outperform | $46 | $30.90 | $31.43 | +1.7% | +4.6% | +10.9% | -3.4% | +1.1% | -0.7% |
| Jul 7 | Wolfe Research | Initiates | Outperform | $45 | $33.41 | $34.32 | +2.7% | +2.6% | -0.3% | -1.3% | -2.3% | -2.1% |
| Apr 27 | H.C. Wainwright | Initiates | Buy | $45 | $30.73 | $30.94 | +0.7% | +3.5% | -1.4% | -2.5% | +3.7% | -0.9% |
| Mar 27 | Stifel | Maintains | Buy → Buy | — | $24.53 | $24.94 | +1.7% | -2.8% | -2.5% | +6.1% | +0.6% | +3.5% |
| Dec 11 | Stifel | Maintains | Buy → Buy | — | $21.36 | $21.69 | +1.5% | -5.3% | -5.4% | +3.8% | -0.2% | -3.9% |
No insider trades available.
8-K · 1.01
! Medium
LB Pharmaceuticals Inc -- 8-K 1.01: Equity Issuance
Jul 29
8-K
LB Pharmaceuticals Inc -- 8-K Filing
Jul 22
8-K
LB Pharmaceuticals Inc -- 8-K Filing
Jun 10
8-K
Unknown — 8-K Filing
LBRX advanced LB-102 into Phase 3 trials following positive Phase 2 data, signaling potential regulatory progress toward market approval that could drive significant upside if efficacy confirms.
Mar 26
8-K
Unknown — 8-K Filing
Extended consulting arrangement for departing executive suggests management continuity concerns and may indicate knowledge gaps the company needs filled, potentially signaling organizational instability to investors.
Mar 16
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
The appointment of Dr. Lenz to LBRX's board signals potential strategic expertise or credibility enhancement, likely positive for stock sentiment if the hire addresses governance gaps or brings relevant industry experience.
Mar 10
8-K · 1.01
! Medium
LB Pharmaceuticals Inc -- 8-K 1.01: Equity Issuance
LB Pharmaceuticals secured $100 million in equity financing through a securities purchase agreement, providing capital for operations and potential development initiatives.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Jpmorgan Chase & Co | 1,427,568 | $33M | Reduced | Mar 2026 |
| 2 | Trails Edge Capital Partners, Lp | 1,319,362 | $33M | Reduced | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 894,653 | $22M | New | Mar 2026 |
| 4 | Alyeska Investment Group, L.p. | 863,947 | $21M | Added | Mar 2026 |
| 5 | Vivo Capital, Llc | 800,000 | $20M | New | Mar 2026 |
| 6 | Nan Fung Group Holdings Ltd | 630,657 | $16M | Added | Mar 2026 |
| 7 | Citadel Advisors Llc | 416,906 | $10M | Added | Mar 2026 |
| 8 | Fmr Llc | 222,508 | $5M | — | Mar 2026 |
| 9 | Northern Trust Corp | 154,398 | $4M | Added | Mar 2026 |
| 10 | Ubs Group Ag | 137,932 | $3M | Added | Mar 2026 |
| 11 | Millennium Management | 136,966 | $3M | New | Mar 2026 |
| 12 | Vanguard Portfolio Management Llc | 112,497 | $3M | New | Mar 2026 |
| 13 | Russell Investments Group, Ltd. | 72,067 | $2M | Added | Mar 2026 |
| 14 | Janus Henderson Group Plc | 65,429 | $2M | New | Mar 2026 |
| 15 | Stempoint Capital Lp | 50,000 | $1M | New | Mar 2026 |
| 16 | Bank Of New York Mellon Corp | 45,457 | $1M | Added | Mar 2026 |
| 17 | Boxer Capital Management, Llc | 70,000 | $1M | New | Sep 2025 |
| 18 | Morgan Stanley | 49,282 | $1M | Added | Dec 2025 |
| 19 | Jane Street Group, Llc | 31,733 | $706K | Added | Dec 2025 |
| 20 | Nuveen, Llc | 22,966 | $566K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.38B
Enterprise Value
$919.2M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.24x
P/B
4.03x
P/S
—
P/FCF
-34.44x
EV/EBITDA
—
Shares Out
25.3M
Financials (TTM)
Revenue
$0
Net Income
-$39.2M
EBITDA
-$39.0M
Free Cash Flow
-$35.3M
Op Cash Flow
-$35.2M
EPS Basic
$-1.00
EPS Diluted
$-21.47
EPS Forward
$-3.83
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$312.9M
Total Liab.
$11.6M
Total Equity
$301.3M
Cash
$295.2M
LT Debt
$0
Book Value/Sh
$11.91
Debt/Equity
0.01x
Current Ratio
41.44
Quick Ratio
41.44
Returns & Growth
ROE
-8.4%
ROA
-8.1%
ROIC
-9.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
+94.4%
Price Returns
2W
+37.1%
1M
+40.5%
3M
+50.1%
6M
+101.5%
12M
+177.5%
Technicals
52W High
$49.14
52W Low
$13.36
50d MA
$33.10
200d MA
$25.53
RSI (14)
88.90
ATR (14)
$3.04
Beta
-0.18
Avg Volume
386K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$38.00
High
$45.00
Low
$31.00
Median
$38.00
Data updated apr 25, 2026 6:36pm
· Source: financialmodelingprep.com